In CNS tumors, a higher amplification was observed for EZH2, while bladder/urinary tract and esophagus/stomach cancers displayed a more frequent amplification of EED and SUZ12. Head and neck tumors demonstrated a higher level of EED amplification than EZH2 and SUZ12. The adrenal gland and bowel cancers, as well as lymphoid and myeloid malignancies showed the lowest percentage of cases with amplification (Figure 1A,B). The gene discussed is SUZ12; the disease is gastric neoplasm.